Why the study?
Do non-vitamin K antagonist oral anticoagulants (NOACs) improve efficacy and safety compared to standard anticoagulation or placebo in patients with atrial fibrillation or VTE?
Population
Patients with antithrombotic indications, including atrial fibrillation, prophylaxis of venous…
Comparison
Non-vitamin K antagonist oral anticoagulants… vs Standard anticoagulation or placebo
Design
Review
Authors
Loading...
May support NOAC preference in AF or VTE; leaves open need for prospective trials before practice change.
Do non-vitamin K antagonist oral anticoagulants (NOACs) improve efficacy and safety compared to standard anticoagulation or placebo in patients with atrial fibrillation or VTE?
NOACs offer substantial benefits for patients with nonvalvular atrial fibrillation or VTE due to equivalent or superior efficacy and safety compared to standard therapy, without the need for regular monitoring.
Bracey et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: